#EsoGuard

Thiard News@F4F

@newsen.bsky.social

1 month ago

PAVmed Strengthens Financial Position by Closing Preferred Stock and Note Financings Successfully PAVmed Inc. announces the successful closure of preferred stock and senior secured note financings, effectively eliminating previous convertible securities and strengthening its balance sheet remarkably.

PAVmed Strengthens Financial Position by Closing Preferred Stock and Note Financings Successfully #USA #New_York #EsoGuard #PAVmed #Veris_Health

Thiard News@F4F

@newsen.bsky.social

1 month ago

Lucid Diagnostics Secures VA Contract to Enhance EsoGuard® Awareness Among Veterans Lucid Diagnostics has received a significant contract from the U.S. Department of Veterans Affairs to expand access to its EsoGuard® test for esophageal precancer, benefiting millions of veterans nationwide.

Lucid Diagnostics Secures VA Contract to Enhance EsoGuard® Awareness Among Veterans #United_States #New_York #Lucid_Diagnostics #EsoGuard #Veterans_Affairs

Thiard News@F4F

@newsen.bsky.social

4 months ago

Lucid Diagnostics Set to Engage Investors at MedTech Forum in NYC Lucid Diagnostics will participate in the upcoming Canaccord Genuity MedTech Forum, emphasizing its cancer prevention endeavors and investor engagements.

Lucid Diagnostics Set to Engage Investors at MedTech Forum in NYC #USA #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

4 months ago

Lucid Diagnostics Reports Strong Financials and Business Updates for Q3 2025 In Q3 2025, Lucid Diagnostics processed nearly 3,000 EsoGuard tests, raising $1.2 million in revenue with positive Medicare coverage developments.

Lucid Diagnostics Reports Strong Financials and Business Updates for Q3 2025 #USA #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lucid Diagnostics to Host Important Investor Call on September 8, 2025, to Discuss Recent Developments On September 8, 2025, Lucid Diagnostics will conduct an investor call to discuss critical outcomes from a recent advisory meeting regarding their cancer detection technology.

Lucid Diagnostics to Host Important Investor Call on September 8, 2025, to Discuss Recent Developments #United_States #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

7 months ago

Lucid Diagnostics Shares Second Quarter 2025 Financial Results and Business Update Lucid Diagnostics reports its Q2 2025 financial results, highlighting progress in cancer detection and upcoming Medicare coverage meetings.

Lucid Diagnostics Shares Second Quarter 2025 Financial Results and Business Update #United_States #New_York #Lucid_Diagnostics #EsoGuard #PAVmed_Inc.

Thiard News@F4F

@newsen.bsky.social

7 months ago

Lucid Diagnostics Announces Participation in Key Investor Conferences Focusing on Cancer Prevention Lucid Diagnostics is set to engage with investors through upcoming conferences, highlighting its innovative cancer prevention approach and key products.

Lucid Diagnostics Announces Participation in Key Investor Conferences Focusing on Cancer Prevention #USA #New_York #Lucid_Diagnostics #EsoGuard #GERD

Thiard News@F4F

@newsen.bsky.social

8 months ago

MolDX Gathers Experts to Review Medicare Coverage for EsoGuard® Esophageal DNA Test MolDX is set to hold a vital meeting with medical experts on September 4, 2025, to reassess Medicare coverage for Lucid Diagnostics' EsoGuard®, focusing on its implications for early esophageal cancer detection.

MolDX Gathers Experts to Review Medicare Coverage for EsoGuard® Esophageal DNA Test #United_States #New_York #Lucid_Diagnostics #EsoGuard #MolDX

Thiard News@F4F

@newsen.bsky.social

8 months ago

Hoag Digestive Health Institute Unveils Innovative Esophageal Cancer Screening Tool to Save Lives Hoag Digestive Health Institute launches EsoGuard, a groundbreaking, non-invasive tool for early detection of esophageal cancer, revolutionizing patient care.

Hoag Digestive Health Institute Unveils Innovative Esophageal Cancer Screening Tool to Save Lives #United_States #Newport_Beach #EsoGuard #Esophageal_Cancer #Hoag_Digestive_Health

Thiard News@F4F

@newsen.bsky.social

8 months ago

Major California Health System Integrates Advanced Esophageal Cancer Precancer Testing Using Lucid Diagnostics' EsoGuard California's healthcare system partners with Lucid Diagnostics to launch a pioneering esophageal precancer testing program, aiming for early detection and prevention.

Major California Health System Integrates Advanced Esophageal Cancer Precancer Testing Using Lucid Diagnostics' EsoGuard #United_States #California #Lucid_Diagnostics #EsoGuard #Hoag_Hospital

Thiard News@F4F

@newsen.bsky.social

10 months ago

Lucid Diagnostics Reports First Quarter 2025 Progress and Financial Highlights Lucid Diagnostics shares significant financial results and business progress for Q1 2025, highlighting advances in cancer prevention diagnostics and upcoming milestones.

Lucid Diagnostics Reports First Quarter 2025 Progress and Financial Highlights #USA #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

10 months ago

Lucid Diagnostics' EsoGuard Esophageal DNA Test Shows Promise in Detecting Precancerous Condition A recent NCI-sponsored study unravels the potential of Lucid Diagnostics' EsoGuard test to detect esophageal precancer in asymptomatic patients, expanding its use.

Lucid Diagnostics' EsoGuard Esophageal DNA Test Shows Promise in Detecting Precancerous Condition #United_States #New_York #Lucid_Diagnostics #EsoGuard #Barrett's_Esophagus

Thiard News@F4F

@newsen.bsky.social

11 months ago

Lucid Diagnostics Unveils Plans for Public Offering to Boost Cancer Prevention Efforts Lucid Diagnostics announces its intention to launch an underwritten public offering for common stock. Proceeds will support cancer prevention.

Lucid Diagnostics Unveils Plans for Public Offering to Boost Cancer Prevention Efforts #USA #New_York #Cancer_Prevention #Lucid_Diagnostics #EsoGuard

Thiard News@F4F

@newsen.bsky.social

11 months ago

Lucid Diagnostics Shares Positive Business Update and 2024 Financial Outcomes Lucid Diagnostics publicly shares a robust business update alongside their fourth-quarter and full-year financial results for 2024. Highlights include revenue growth and strategic partnerships.

Lucid Diagnostics Shares Positive Business Update and 2024 Financial Outcomes #United_States #New_York #Cancer_Prevention #Lucid_Diagnostics #EsoGuard

Thiard News@F4F

@newsen.bsky.social

11 months ago

Updated NCCN Guidelines Now Include Screening for Esophageal Precancer Using Lucid Diagnostics' Innovative Test Lucid Diagnostics announces that the updated NCCN guidelines now recommend esophageal precancer screening using its EsoGuard test, enhancing cancer detection methods.

Updated NCCN Guidelines Now Include Screening for Esophageal Precancer Using Lucid Diagnostics' Innovative Test #USA #New_York #Lucid_Diagnostics #EsoGuard #NCCN_Guidelines

Thiard News@F4F

@newsen.bsky.social

11 months ago

Lucid Diagnostics Achieves Critical Publication on EsoGuard® for Esophageal Precancer Testing Lucid Diagnostics announces the acceptance of their ENVET-BE study for peer-reviewed publication, demonstrating EsoGuard®'s efficacy in esophageal precancer detection.

Lucid Diagnostics Achieves Critical Publication on EsoGuard® for Esophageal Precancer Testing #USA #New_York #Lucid_Diagnostics #EsoGuard #Esophageal_Cancer

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Completes $15.3 Million Direct Stock Offering to Boost Operations Lucid Diagnostics has successfully closed a $15.3 million direct stock offering, aiming to enhance working capital and support corporate needs.

Lucid Diagnostics Completes $15.3 Million Direct Stock Offering to Boost Operations #United_States #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Announces Significant $15.3 Million Direct Stock Offering to Boost Cancer Prevention Initiatives Lucid Diagnostics has declared a direct stock offering worth $15.3 million, aiming to enhance its cancer prevention technologies and operations.

Lucid Diagnostics Announces Significant $15.3 Million Direct Stock Offering to Boost Cancer Prevention Initiatives #United_States #New_York #Lucid_Diagnostics #EsoGuard #PAVmed

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Receives $8 Million NIH Grant for Groundbreaking Esophageal Cancer Study Lucid Diagnostics has received an $8 million NIH grant for a clinical trial aimed at improving esophageal precancer detection in at-risk patients without chronic GERD symptoms.

Lucid Diagnostics Receives $8 Million NIH Grant for Groundbreaking Esophageal Cancer Study #USA #New_York #NIH_Grant #Lucid_Diagnostics #EsoGuard

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Achieves Compliance with Nasdaq Listing Requirements After Price Recovery Lucid Diagnostics Inc. has officially regained compliance with Nasdaq's minimum bid price requirement, ensuring continued trading of its stock under symbol LUCD.

Lucid Diagnostics Achieves Compliance with Nasdaq Listing Requirements After Price Recovery #USA #New_York #NASDAQ #Lucid_Diagnostics #EsoGuard

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics Partners with LEAA Health to Offer EsoGuard Testing in Concierge Medicine Lucid Diagnostics has signed a contract with LEAA Health to provide EsoGuard esophageal precancer testing, enhancing personalized patient care, focusing on prevention.

Lucid Diagnostics Partners with LEAA Health to Offer EsoGuard Testing in Concierge Medicine #USA #New_York #Lucid_Diagnostics #EsoGuard #LEAA_Health

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics to Showcase Innovations at the BTIG MedTech Conference in Snowbird Lucid Diagnostics Inc. announces its participation in the BTIG MedTech Conference, highlighting innovations in cancer prevention diagnostics on February 11-12.

Lucid Diagnostics to Showcase Innovations at the BTIG MedTech Conference in Snowbird #United_States #Lucid_Diagnostics #EsoGuard #PAVmed_Inc. #Snowbird,_Utah

Thiard News@F4F

@newsen.bsky.social

1 year ago

Lucid Diagnostics EsaGuard Test's Clinical Utility Study Accepted for Peer Review Publication: A Major Step Forward in Esophageal Cancer Screening The EsoGuard Esophageal DNA Test by Lucid Diagnostics is validated through a new clinical study showcasing impressive patient compliance rates and effectiveness in esophageal cancer screening.

Lucid Diagnostics EsaGuard Test's Clinical Utility Study Accepted for Peer Review Publication: A Major Step Forward in Esophageal Cancer Screening #USA #New_York #Lucid_Diagnostics #EsoGuard #Esophageal_Cancer